In Acta pharmacologica Sinica
As a major class of medicine for treating the lethal type of castration-resistant prostate cancer (PCa), long-term use of androgen receptor (AR) antagonists commonly leads to antiandrogen resistance. When AR signaling pathway is blocked by AR-targeted therapy, glucocorticoid receptor (GR) could compensate for AR function especially at the late stage of PCa. AR-GR dual antagonist is expected to be a good solution for this situation. Nevertheless, no effective non-steroidal AR-GR dual antagonist has been reported so far. In this study, an AR-GR dual binder H18 was first discovered by combining structure-based virtual screening and biological evaluation. Then with the aid of computationally guided design, the AR-GR dual antagonist HD57 was finally identified with antagonistic activity towards both AR (IC50 = 0.394 μM) and GR (IC50 = 17.81 μM). Moreover, HD57 could effectively antagonize various clinically relevant AR mutants. Further molecular dynamics simulation provided more atomic insights into the mode of action of HD57. Our research presents an efficient and rational strategy for discovering novel AR-GR dual antagonists, and the new scaffold provides important clues for the development of novel therapeutics for castration-resistant PCa.
Chai Xin, Hu Xue-Ping, Wang Xin-Yue, Wang Hua-Ting, Pang Jin-Ping, Zhou Wen-Fang, Liao Jia-Ning, Shan Lu-Hu, Xu Xiao-Hong, Xu Lei, Xia Hong-Guang, Hou Ting-Jun, Li Dan
2023-Jan-13
androgen receptor, antiandrogen resistance, dual antagonists, glucocorticoid receptor, prostate cancer
